[4][3] Beremagene geperpavec is a genetically modified (engineered in a laboratory) herpes-simplex virus used to deliver normal copies of the COL7A1 gene to the wounds.
[3] The most common adverse reactions include itching, chills, redness, rash, cough and runny nose.
[2][3] Beremagene geperpavec is indicated for the treatment of wounds in people with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
In the study, two dystrophic epidermolysis bullosa wounds of comparable size on each participant were identified and randomized to receive either topical administration of beremagene geperpavec or the placebo on a weekly basis.
[3] The FDA granted the approval of Vyjuvek to Krystal Biotech, Inc.[3] This article incorporates public domain material from the United States Department of Health and Human Services